Medpace Holdings, Inc.: Beat — EPS $4.84, Revenue $716M
Earnings BeatQ3 2026 · After-market
@trystockwhiz
Did Medpace Holdings, Inc. (MEDP) beat earnings today?
Yes, Medpace Holdings, Inc. (MEDP) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+9.26% surprise
$4.84Actual
Expected: $4.43
vs. year ago +25.4%
Total Revenue+0.22% surprise
$716MActual
Expected: $714.44M
vs. year ago +8.5%
Released Oct 21 · 4:15 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $716.00M | $659.90M | +8.5% |
| GAAP Basic EPS | $4.92 | $3.95 | +24.6% |
| GAAP Diluted EPS | $4.84 | $3.86 | +25.4% |
| Net Income | $137.46M | $111.14M | +23.7% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY 2026 Outlook |
|---|---|---|
| Revenue | — | $2.835B-$2.855B (+12.0%-12.8% YoY) |
| Net Income | — | $514.0M-$524.0M |
| EBITDA | — | $638.0M-$652.0M |
| Diluted EPS | — | $17.97-$18.32 |
| Interest Income | — | $22.9M |
| Diluted Shares | — | 28.6M |
Business Highlights
- ➤Reported $873.4 million in net new business awards.
- ➤Backlog conversion rate was 23.8%.
- ➤Backlog reached $3,167.2 million at September 30, 2026.
- ➤Board authorized a new $1.0 billion share repurchase program through December 31, 2028.
- ➤New repurchases may use open-market, privately negotiated, Rule 10b5-1, or other transactions.
- ➤Medpace employs approximately 6,600 people across 46 countries.
- ➤Provides Phase I-IV clinical development services to biotechnology, pharmaceutical, and medical-device industries.
- ➤Operating approach leverages regulatory and therapeutic expertise across major disease areas.